Found: 6
Select item for more details and to access through your institution.
Combination of the PD‐1 inhibitor Nivolumab and Immunomodulatory Drug Lenalidomide in Relapsed Hodgkin and Large B‐cell Lymphoma: Results from a Phase I/II Study.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 597, doi. 10.1002/hon.3164_447
- By:
- Publication type:
- Article
WAVELINE‐004: OPEN‐LABEL, PHASE 2 STUDY OF ZILOVERTAMAB VEDOTIN (MK‐2140) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL).
- Published in:
- Hematological Oncology, 2023, v. 41, p. 208, doi. 10.1002/hon.3163_136
- By:
- Publication type:
- Article
OUTCOMES OF AUTOLOGOUS TRANSPLANT, ALLOGENEIC TRANSPLANT, AND CAR T CELL THERAPY IN TP53 ALTERED MANTLE CELL LYMPHOMA: A MULTI‐INSTITUTION RETROSPECTIVE ANALYSIS.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 156, doi. 10.1002/hon.3163_103
- By:
- Publication type:
- Article
A SINGLE‐CENTER RETROSPECTIVE ANALYSIS OF THE TOXICITY OF HIGH‐DOSE METHOTREXATE (HDMTX) ADMINISTERED ON THE FIRST DAY OF (R)CHOP IN AGGRESSIVE NONHODGKIN LYMPHOMAS (ANHLS)
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.92_2880
- By:
- Publication type:
- Article
MAINTENANCE RITUXIMAB IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA PATIENTS RESPONDING TO INDUCTION THERAPY WITH BENDAMUSTINE + RITUXIMAB (BR).
- Published in:
- Hematological Oncology, 2019, v. 37, p. 405, doi. 10.1002/hon.75_2631
- By:
- Publication type:
- Article
MAINTENANCE RITUXIMAB IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA PATIENTS RESPONDING TO INDUCTION THERAPY WITH BENDAMUSTINE + RITUXIMAB (BR).
- Published in:
- Hematological Oncology, 2019, v. 37, p. 405, doi. 10.1002/hon.75_2631
- By:
- Publication type:
- Article